Rohit Loomba
机构：University of California San Diego, University of California San Diego Medical Center
发表论文 24 篇 · 总被引 4 次 · h-index 1
代表论文
- Propelling MASLD trials into the era of non-invasive tests (2026 · The Lancet. Gastroenterology & hepatology · 被引 1)
- WED-043 Combining vibration controlled transient elastography and enhanced liver fibrosis score lowers the false positive rate for identifying MASLD with significant fibrosis in patients with class 2 or higher obesity (2026 · Journal of Hepatology · 被引 1)
- FRI-179 Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirompredict improvements in MASH and liver fibrosis (2026 · Journal of Hepatology · 被引 1)
- OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (2026 · Journal of Hepatology · 被引 1)
- WED-141 Patients with compensated MASH cirrhosis and Fibroscan® VCTE score <15 kPa: baseline data from a phase 3 double-blinded randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis) (2026 · Journal of Hepatology)
- WED-042 Use of the ANTICIPATE NASH risk score to stratify patients with compensated MASH cirrhosis: data from a phase 3, doubleblinded, randomized clinical trial assessing the safetyand efficacy of pegozafermin (ENLIGHTEN-cirrhosis) (2026 · Journal of Hepatology)